Advice
The Joint Committee on Vaccination and Immunisation (JCVI) has been notified of the discontinuation of Menitorix© (Hib/MenC). This necessitates a change to the routine infant schedule as this vaccine is currently given at 12 months.
After careful consideration of the options, the JCVI advises that:
- an additional dose of Hib-containing multivalent vaccine should be offered at 12 or 18 months of ages – note that giving this at 18 months would require the creation of a new immunisation visit
- the second dose of measles, mumps and rubella (MMR) vaccine should be brought forwards from 3 years 4 months to 18 months of age to improve coverage
- based on the demonstrated decline of invasive meningococcal A, C, W and Y disease in the UK (primarily due to the success of the teenage MenACWY vaccination programme) and subsequent low number of cases to prevent, including a dose of MenC-containing vaccine (such as MenACWY) in the infant schedule is not recommended – efforts to sustain and improve coverage of MenACWY in adolescents are important to maintain herd immunity
Published: Aug 18, 2022
We use cookies to make this site work. We'd also like to set optional cookies so we can understand how the site is used and improve it. We will not set optional cookies unless you accept them. You can change your choice at any time from the Cookie settings link in the footer.
Strictly necessary cookies
These cookies are required for the site to work. They store your cookie preferences and keep your session secure. They are exempt from consent under PECR Regulation 6(4) because they are essential to deliver the service you have requested.
Optional cookies
Optional cookies help us understand how the site is used and provide additional features such as analytics, accessibility tools and translation. We will only set them if you accept.